Avalyn Pharma names Robert Meyer to board
Avalyn Pharma adds independent director Robert Meyer, M.D., and outlines his cash and equity compensation under its non-employee director policy.
Rhea-AI Filing Summary
Avalyn Pharma Inc. (AVLN) disclosed that on September 15, 2026, its board appointed Robert Meyer, M.D. as a Class II director, with a term expiring at the 2028 annual meeting of stockholders. The board determined that he is independent under Nasdaq listing standards.
Dr. Meyer has extensive regulatory and pulmonary drug-development experience, including senior roles at the U.S. Food and Drug Administration and Merck & Co., Inc., and prior board service at several public life sciences companies. Under Avalyn’s Non-Employee Director Compensation Policy, he will receive a $40,000 annual cash retainer and received an initial stock option for 31,182 shares vesting over three years. He will also be eligible for annual option grants for 15,591 shares, vesting on the earlier of the first anniversary of grant or the next annual meeting, while he remains a director. Each option will have an exercise price equal to the fair market value of Avalyn common stock on the grant date.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Annual cash retainer: $40,000
Initial stock option grant: 31,182 shares
Annual stock option grant: 15,591 shares
+2 more
5 metrics
Annual cash retainer
$40,000
Annual retainer for serving on Avalyn Pharma’s board under the Non-Employee Director Compensation Policy
Initial stock option grant
31,182 shares
Option to purchase shares of common stock granted to Robert Meyer, M.D. on the Effective Date
Annual stock option grant
15,591 shares
Eligible annual option grant for Robert Meyer, M.D. on each annual meeting date while he remains a director
Initial grant vesting period
3 years
Initial stock option vests in equal annual installments over three years from the date of grant
Class of directorship
Class II director
Dr. Meyer appointed as a Class II director with term expiring at the 2028 annual meeting of stockholders
Key Terms
Class II director, Non-Employee Director Compensation Policy, Fair Market Value, indemnification agreement, +1 more
5 terms
Class II director regulatory
"the Board appointed Robert Meyer, M.D. to the Board as a Class II director"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Non-Employee Director Compensation Policy financial
"Under the Company’s Non-Employee Director Compensation Policy (the “Compensation Policy”)"
Fair Market Value financial
"exercise price equal to the Fair Market Value of the Common Stock on the date of grant"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
indemnification agreement regulatory
"Dr. Meyer has entered into an indemnification agreement with the Company"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Avalyn Pharma (AVLN) announce in this 8-K?
Avalyn Pharma reported that on September 15, 2026, its board appointed Robert Meyer, M.D. as a Class II director for a term expiring at the 2028 annual meeting of stockholders, and the board determined he is independent under Nasdaq listing standards.
What is the compensation for Avalyn Pharma (AVLN) director Robert Meyer, M.D.?
Under Avalyn’s Non-Employee Director Compensation Policy, Dr. Meyer is eligible for a $40,000 annual cash retainer and received an initial stock option to purchase 31,182 shares of common stock, plus eligibility for annual option grants of 15,591 shares while he remains a director.
How do Robert Meyer’s stock options at Avalyn Pharma (AVLN) vest?
The initial option grant for 31,182 shares vests in equal annual installments over three years. Each annual grant for 15,591 shares to continuing non-employee directors generally vests in full on the earlier of the first anniversary of grant or the next annual meeting.
What experience does Avalyn Pharma (AVLN) highlight for new director Robert Meyer, M.D.?
Avalyn cites Dr. Meyer’s experience at the U.S. Food and Drug Administration, his role as Vice President and Head of Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories, and his board service at other public life sciences companies as reasons he is qualified to serve.
Will Avalyn Pharma (AVLN) use a set price for Robert Meyer’s stock options?
Each option granted under the Non-Employee Director Compensation Policy will have a per-share exercise price equal to the Fair Market Value of Avalyn’s common stock on the relevant grant date, as defined in the company’s 2026 Stock Option and Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
